Clinical Research Directory

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

Sponsor: Genetix Biotherapeutics Inc.

Summary

The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.

Official title: A Safety and Effectiveness Registry Study of Patients with Β-Thalassemia Treated with Betibeglogene Autotemcel (the Glostar Registry)

Key Details

Conditions

Interventions

Locations (6)